Citadel Advisors’s Structure Therapeutics GPCR Stock Holding History

Citadel Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.62M	Sell	54,300 -500	-0.9%	-$34.2K	﹤0.01%	5528
2025 Q4	$3.81M	Sell	54,800 -28,600	-34%	-$1.17M	﹤0.01%	4749
2025 Q3	$2.34M	Sell	83,400 -5,700	-6%	-$114K	﹤0.01%	5752
2025 Q2	$1.85M	Sell	89,100 -28,200	-24%	-$620K	﹤0.01%	5846
2025 Q1	$2.03M	Sell	117,300 -30,900	-21%	-$757K	﹤0.01%	5507
2024 Q4	$4.02M	Buy	148,200 +80,700	+120%	+$2.86M	﹤0.01%	4327
2024 Q3	$2.96M	Sell	67,500 -25,900	-28%	-$1M	﹤0.01%	4805
2024 Q2	$3.67M	Buy	93,400 +44,800	+92%	+$1.84M	﹤0.01%	4249
2024 Q1	$2.08M	Buy	48,600 +24,100	+98%	+$1.02M	﹤0.01%	5436
2023 Q4	$999K	Buy	+24,500	New	+$1.4M	﹤0.01%	6683

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's GPCR Position: Q1 2026 in Review

Citadel Advisors sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 772,518 shares — an estimated $52.9M sold.

Citadel Advisors first reported a position in GPCR in Q1 2023 and held it in 12 quarters. The position peaked at $63.7M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Citadel Advisors reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 772,518 Structure Therapeutics shares in Q1 2026, an estimated $52.9M.
Citadel Advisors first reported a position in Structure Therapeutics in Q1 2023 and held it in 12 quarters.
Citadel Advisors's Structure Therapeutics position peaked at $63.7M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.